
Biocon secures 10-year Brazil deal for Pertuzumab with 100% PDP allocation
Biocon has partnered with Brazil’s Bahiafarma and Bionovis for the local manufacture and commercialisation of Pertuzumab under a 10-year government-backed programme, opening access to around 70% of the drug’s demand in Brazil’s public healthcare system.








